These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15264190)

  • 1. Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists.
    Martirosyan HA; Brass EP; Mehrotra R; Adler SG;
    Am J Kidney Dis; 2004 Aug; 44(2):309-21. PubMed ID: 15264190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?
    Rosansky SJ
    Blood Purif; 1996; 14(4):315-20. PubMed ID: 8873957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How to motivate nephrologists to think more "cardiac" and cardiologists to think more "renal"?].
    Kes P; Milicić D; Basić-Jukić N
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():85-9. PubMed ID: 23120822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.
    Roy P; Bouchard J; Amyot R; Madore F
    Am J Kidney Dis; 2006 Oct; 48(4):645-51. PubMed ID: 16997061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore.
    Bellotti P; Badano LP; Acquarone N; Griffo R; Lo Pinto G; Maggioni AP; Mattiauda C; Menardo G; Mombelloni P;
    Eur Heart J; 2001 Apr; 22(7):596-604. PubMed ID: 11259147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hypertension in patients with CKD: differences between primary and tertiary care settings.
    Minutolo R; De Nicola L; Zamboli P; Chiodini P; Signoriello G; Toderico C; Arfè G; Boschi G; Brancati C; Iaccarino P; Conte G
    Am J Kidney Dis; 2005 Jul; 46(1):18-25. PubMed ID: 15983953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
    Berger AK; Duval S; Krumholz HM
    J Am Coll Cardiol; 2003 Jul; 42(2):201-8. PubMed ID: 12875751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
    Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T
    Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
    Wang AY; Li PK; Lui SF; Sanderson JE
    Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal change in left ventricular hypertrophy in the elderly on antihypertensive therapy.
    Ahmad A; Nawaz HM; Nevins L; Nawaz H
    Conn Med; 2003 Feb; 67(2):67-73. PubMed ID: 12664833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and treatment of coronary artery disease in patients with end-stage renal disease.
    McCullough PA
    Kidney Int Suppl; 2005 Jun; (95):S51-8. PubMed ID: 15882314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal disease and the heart.
    Woolfson RG
    Hosp Med; 1999 Feb; 60(2):85-9. PubMed ID: 10320836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
    Ahmed A
    J Am Geriatr Soc; 2003 Jan; 51(1):123-6. PubMed ID: 12534856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice.
    Rutten FH; Grobbee DE; Hoes AW
    Eur J Heart Fail; 2003 Jun; 5(3):337-44. PubMed ID: 12798832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
    Karpov IuA
    Kardiologiia; 2005; 45(12):87-92. PubMed ID: 16353053
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodialysis-associated hypertension: pathophysiology and therapy.
    Hörl MP; Hörl WH
    Am J Kidney Dis; 2002 Feb; 39(2):227-44. PubMed ID: 11840363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.